This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Covid-19 vaccine (recombinant spike protein, adjuvanted)

Updated 2 Feb 2023 | Coronavirus vaccine


Vaccine containing COVID-19 (recombinant spike protein, adjuvanted).

Drugs List

  • COVID-19 NUVAXOVID VACCINE (ADJUVANTED) 5micrograms/0.5ml dose dispersion for inj multidose vial
  • generic covid-19 nuvaxovid vaccine (adjuvanted) dispersion for injection multidose vial
  • Therapeutic Indications


    Coronavirus disease 2019 (COVID-19): Prophylaxis

    For comprehensive information or advice on this product or the immunisation programme in the UK, the following website should be accessed.
    Available at



    2 doses (0.5ml each), administered 3 weeks apart.


    Administered via intramuscular injection.


    Children under 18 years

    Precautions and Warnings

    Acute infection
    Recent anticoagulant therapy
    Severe febrile conditions
    Immunodeficiency syndromes

    Postpone immunisation if there is active or suspected infection
    Advise ability to drive/operate machinery may be affected by side effects
    Avoid second dose if anaphylaxis occurs with first dose
    Avoid within 90 days after casirivimab and imdevimab therapy
    Impaired response possible in immunocompromised patients
    Vaccine may not be effective in 100% of patients
    Different brands may not be interchangeable
    Do not mix with other vaccines in the same syringe
    Record name and batch number of administered product
    Resuscitation facilities must be immediately available
    Monitor patient for at least 15 minutes after vaccination
    Management of cases of shock should follow current medical standards
    Follow national immunisation guidelines

    If anaphylaxis occurs following the first dose of the vaccine, do not administer the second dose.

    Precautions should be in place to avoid injury from fainting should a psychogenic response occur from the needle injection.

    Pregnancy and Lactation


    Use COVID-19 vaccine (recombinant spike protein, adjuvanted) with caution during pregnancy.

    The manufacturer does not recommend using COVID-19 vaccine (recombinant spike protein, adjuvanted) during pregnancy unless the potential benefits outweigh any potential risks to the mother or foetus. At the time of writing there is limited published information regarding the use of COVID-19 vaccine (recombinant spike protein, adjuvanted) during pregnancy. Potential risks are unknown.


    Use COVID-19 vaccine (recombinant spike protein, adjuvanted) with caution during breastfeeding.

    The presence of COVID-19 vaccine (recombinant spike protein, adjuvanted) in human breast milk and its effects on exposed infants are unknown.

    Side Effects

    Local pain (injection site)
    Painful extremities
    Swelling (injection site)
    Tenderness (injection site)


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: February 2022

    Reference Sources

    Summary of Product Characteristics: Nuvaxovid dispersion for injection. Novavax. Revised February 2022.

    Immunisation against infectious disease - The Green Book.
    Available at
    Last accessed: 10 February 2022.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.